Two Sigma Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Two Sigma Securities’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,599	Closed	-$250K	–	1964
2020 Q4	$250K	Sell	1,599 -3,292	-67%	-$423K	0.01%	1186
2020 Q3	$560K	Buy	+4,891	New	+$528K	0.01%	549
2019 Q4	–	Sell	-11,513	Closed	-$1.23M	–	2749
2019 Q3	$1.13M	Buy	+11,513	New	+$1.3M	0.01%	821
2019 Q1	–	Sell	-7,310	Closed	-$909K	–	2617
2018 Q4	$712K	Buy	+7,310	New	+$864K	0.01%	811
2018 Q3	–	Sell	-15,691	Closed	-$1.97M	–	3160
2018 Q2	$1.95M	Buy	+15,691	New	+$1.83M	0.01%	941
2017 Q3	–	Sell	-3,334	Closed	-$406K	–	1308
2017 Q2	$406K	Buy	+3,334	New	+$388K	0.08%	255
2016 Q4	–	Sell	-3,158	Closed	-$387K	–	1019
2016 Q3	$387K	Sell	3,158 -70	-2%	-$9.01K	0.13%	222
2016 Q2	$377K	Buy	+3,228	New	+$458K	0.21%	144
2016 Q1	–	Sell	-1,235	Closed	-$236K	–	432
2015 Q4	$236K	Buy	+1,235	New	+$216K	0.28%	98

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Securities's ALXN Position: Q1 2021 in Review

Two Sigma Securities sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,599 shares — an estimated $250K sold.

Two Sigma Securities first reported a position in ALXN in Q4 2015 and held it in 9 quarters. The position peaked at $1.95M in Q2 2018. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Two Sigma Securities reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Two Sigma Securities sold 1,599 Alexion Pharmaceuticals shares in Q1 2021, an estimated $250K.
Two Sigma Securities first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 9 quarters.
Two Sigma Securities's Alexion Pharmaceuticals position peaked at $1.95M in Q2 2018.
754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Two Sigma Securities's 13F filing for Q1 2021, filed 17 May 2021.